Used in targeted cancer therapies, particularly for hematologic malignancies such as acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Binds specifically to the IL-3 receptor alpha chain (CD123), which is overexpressed on leukemic stem cells and certain immune-derived cancer cells. This selective binding enables the antibody to deliver cytotoxic agents directly to tumor cells when used as part of antibody-drug conjugates (ADCs), or to flag cancer cells for destruction by the immune system through mechanisms like antibody-dependent cellular cytotoxicity (ADCC). Also investigated in chimeric antigen receptor (CAR) T-cell therapies where it serves as a targeting domain to direct engineered T cells to CD123-positive malignancies. Its high specificity makes it valuable in minimizing damage to healthy tissues while improving therapeutic efficacy.